Hypotensive shock and angio-oedema from angiotensin II receptor blocker: A class effect in spite of tripled tryptase values

Journal of Internal Medicine

Volumn 258, Issue 4, 2005, Pages 385-387

  Nielsen, Erik W ^a,b  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Adverse effects; Angioneurotic oedema; Angiotensin II type 1 receptor blockers; Bradykinin; Differential diagnosis; Shock

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRADYKININ; IMMUNOGLOBULIN E; IRBESARTAN; NORADRENALIN; TRYPTASE;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEGRANULATION; FEMALE; HUMAN; HYPERTENSION; LABORATORY TEST; MAST CELL; PRIORITY JOURNAL; SHOCK; SKIN TEST;

ANGIONEUROTIC EDEMA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; FEMALE; HUMANS; HYPOTENSION; MAST CELLS; MIDDLE AGED; NOREPINEPHRINE; SERINE ENDOPEPTIDASES; SHOCK; SKIN TESTS; TETRAZOLES; TRYPTASES;

EID: 25444474467     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01547.x     Document Type: Article

References (14)

1. Nussberger J, Koike H. Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil. Clin Ther 2004; 26(Suppl. A): A12-20.
2. MacLean JA, Hannaway PJ. Angioedema and AT1 receptor blockers: proceed with caution. Arch Intern Med 2003; 163: 1488-9.
3. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-7.
4. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005; 111: 315-20.
5. Batenburg WW, Tom B, Schuijt MP, Danser AH. Angiotensin II type 2 receptor-mediated vasodilation. Focus on bradykinin, NO and endothelium-derived hyperpolarizing factor(s). Vascul Pharmacol 2005; 42: 109-18.
6. Walther T, Siems WE, Hauke D et al. AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats. FASEB J 2002; 16: 1237-41.
7. Skidgel RA. Bradykinin-degrading enzymes - structure, function, distribution, and potential roles in cardiovascular pharmacology. J Cardiovasc Pharmacol 1992; 20: S4-9.
8. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000; 356: 608-9.
9. Icatibant: HOE 140, JE 049. JE049. Drugs R D 2004; 5: 343-8.
10. Brown SG, Blackman KE, Heddle RJ. Can serum mast cell tryptase help diagnose anaphylaxis? Emerg Med Australas 2004; 16: 120-4.
11. Johansson SGO, Hourihane JO, Bousquet J et al. A revised nomenclature for allergy: An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813-24.
12. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 2001; 25: 553-62.
13. Regner KR, Riegert-Johnson DL, Volcheck GW. Serial measurement of serum tryptase in angiotensin-converting enzyme inhibitor-associated angioedema. Mayo Clin Proc 2003; 78: 655-6.
14. Bandeira-Melo C, Calheiros AS, Silva PMR, Cordeiro RSB, Teixeira MM, Martins MA. Suppressive effect of distinct bradykinin B2 receptor antagonist on allergen-evoked exudation and leukocyte infiltration in sensitized rats. Br J Pharmacol 1999; 127: 315-20.